About Glycadia  |  Officers

Benjamin F. McGraw, III, Pharm.D., Chief Executive Officer

Benjamin F. McGraw, III, previously was the Managing Member, Long Shadows Asset Management, LLC and portfolio manager for Long Shadows Partners, LP. Before that, he was Chairman, President & CEO of Valentis. He formed Valentis through mergers and acquisitions of three companies and various technologies beginning in 1994. Prior to this, Dr. McGraw gained experience in corporate development as Corporate Vice President for Corporate Development for Allergan, a pharmaceutical company. Before that, he was an analyst and a fund manager at Carerra Capital Management. He began his career in pharmaceutical R&D, holding various positions including Vice President, Development for Marion Laboratories and Marion Merrell Dow, both pharmaceutical companies. Dr. McGraw earned his Bachelor of Science and Doctor of Pharmacy degrees from the University of Tennessee Center for the Health Sciences where he also completed a clinical practice residency.

Margo Cohen, MD, Chief Scientific Officer

Dr. Margo Cohen is a co-founder of the Company. She has been Professor of Medicine and Director of Endocrinology and Metabolism at the University of Medicine and Dentistry of New Jersey and at Wayne State University School of Medicine (Detroit), Adjunct Professor at the University of Pennsylvania, and Visiting Professor at the University of Tel Aviv. She has been Principal Investigator in numerous clinical trials for New Drug Applications sponsored by the pharmaceutical industry, has led investigative programs, discovery, preclinical and clinical development of new drug products and medical devices, and has overseen design and execution of several Investigational New Drug Applications and safety/efficacy protocols. She has served on numerous study sections and advisory committees of the National Institutes of Health, the American Diabetes Association, and the Juvenile Diabetes Foundation and was twice appointed Chair of the Board of Scientific Counselors of a member NIH Institute, where her responsibilities have included review and evaluation of scientific and technological programs and timely achievement of programmatic goals. Dr. Cohen has been editor-in chief of the journal Endocrinology and has been appointed to the editorial boards of the journals Diabetes and Endocrinology and other professional journals. Dr. Cohen has authored more than 130 publications and ten books in the areas of diabetes, endocrinology, and biochemistry, and her investigative contributions, which have been competitively funded by the NIH for thirty years, have been recognized with several awards. She is a Fulbright scholar. She received her B.S. and M.D. from the University of Michigan and completed doctoral studies in Biochemistry at Wayne State University and the University of Buenos Aires.

Perry Cohen, Senior Vice-President, Finance and Corporate Development

Mr. Cohen is a co-founder of the Company and was formerly Director of Equity Research at Tradition Asiel Securities, Inc., a New York securities brokerage firm. Mr. Cohen previously held investment management and securities research positions in other securities investment firms, and corporate finance positions including Corporate Credit Manager, Chrysler Corporation, Controller-International, Chrysler Financial Corporation and Director of Finance, Chrysler Argentina. Earlier, Mr. Cohen was a Certified Public Accountant with the public accounting firm of Touche, Ross & Co (now Deloitte & Touche). He received an M.B.A. in Finance from the University of Michigan.

Clyde Shearman, PhD, Vice-President, Development

Dr. Shearman is a research and development executive with 20 years of experience in the areas of molecular biology, immunology and oncology. He has been Director of Research at Sterling Winthrop, Immunoconjugates Division, with responsibility for divisional research and development, new product discovery and patent strategy. He was previously associated with Genzyme Corp., where he was Group Leader for Protein-Antibody Engineering and worked on humanized antibody therapeutics for transplant rejection, graft versus host disease and hepatitis B infection, as well as recombinant Ceredase, an enzyme therapeutic for Gaucher's disease. He was also a Senior Research Scientist at Centocor, Inc., where he developed Panorex, a chimeric antibody therapeutic for colorectal cancer. Dr. Shearman received his B.A. in Biology and Chemistry from the University of Virginia and his Ph.D. in Biochemistry and Microbiology from Thomas Jefferson University and Medical College.

Van-Yu Wu, PhD, Vice-President, Research

Dr. Wu is a highly published protein chemist and biologist. Previously, Dr. Wu was Senior Research Associate at the University of Medicine and Dentistry of New Jersey and at Wayne State University School of Medicine in Detroit, Michigan. Dr. Wu received his B.S. from the University of Taiwan, an M.S. from the University of Detroit and a Ph.D. from Wayne State University. He has been a research investigator for the National Kidney Foundation and Principal Investigator for research sponsored by the NIH.